{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"130"},{"groupId":"OG001","value":"96"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"299"},{"groupId":"OG001","value":"303"}],"units":"Participants"}],"description":"The DC is defined as the number of subjects with a best response rating of CR, PR, or SD that is maintained at least 28 days from the first manifestation of that rating.","groups":[{"description":"Sorafenib 400 mg was administered orally at a dose of 400 mg (2 x 200 mg tablets) twice daily; 2 dose reductions to predefined levels of 400 mg once daily (OD) and 400 mg every other day were permitted for adverse events related to study treatment. Follow-up / Open Label phase: Subjects on sorafenib who continued the study, continued on the same dose of sorafenib as during the double-blind study.","id":"OG000","title":"Sorafenib (Nexavar, BAY43-9006)"},{"description":"Sorafenib-matching placebo tablets were orally administered twice daily (bid). Follow-up / Open Label phase: Subjects on placebo who chose to switch to sorafenib, received an oral dose of 400 mg (2 x 200 mg tablets) bid; similar to the double-blind study.","id":"OG001","title":"Placebo"}],"paramType":"NUMBER","populationDescription":"The disease control rate for the ITT population was determined by independent radiological review and also by investigator assessment (both by using response evaluation criteria in solid tumors (RECIST) up to the cutoff date of 09 Feb 2007","reportingStatus":"POSTED","timeFrame":"from randomization to end of treatment up to the data cutoff date approximately 23 months after start of enrollment","title":"Disease Control (DC)","type":"POST_HOC","unitOfMeasure":"Participants"}